Ginkgo Bioworks Holdings, Inc.

Name: Ginkgo Bioworks Holdings, Inc. standardized financial statements, quarterly
Creator: Listed

DNANYSECIK 1830214HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$20.2m, Q2 FY2026

Operating income−$58.5m, Q2 FY2026

Net income−$46.7m, Q2 FY2026

Ginkgo Bioworks Holdings, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	55.4	34.8	37.9	56.2	89.0	43.8	38.2	39.1	38.8	33.4	19.5	20.2
Cost of revenue	$m	not reported	not reported	not reported	not reported	not reported	not reported	4.1	5.4	not reported	not reported	3.1	1.7
Research and development	$m	157	117	136	134	77.0	76.4	70.9	53.4	69.4	50.1	49.9	46.2
Operating income	$m	(286)	(178)	(178)	(223)	(55.2)	(104)	(81.0)	(58.2)	(90.0)	(70.8)	(71.4)	(58.5)
Interest expense	$m	(15.0)	44.0	not reported	(10.3)	(9.3)	31.4	not reported	not reported	not reported	not reported	not reported	not reported
Income tax	$m	(0.0)	(0.2)	0.0	0.2	(0.4)	(0.3)	0.1	(0.3)	0.0	(0.6)	(0.1)	0.1
Net income	$m	(303)	(212)	(166)	(217)	(56.4)	(108)	(91.0)	(60.3)	(80.8)	(80.8)	(82.6)	(46.7)
Diluted EPS	$ per share	(6.21)	not reported	(3.32)	(4.23)	(1.08)	not reported	(1.68)	(1.10)	(1.45)	not reported	not reported	not reported
Basic EPS	$ per share	(6.21)	not reported	(3.31)	(4.23)	(1.08)	not reported	(1.68)	(1.10)	(1.45)	not reported	(1.39)	(0.75)

Balance sheet

Cash and equivalents$84.5m, Q2 FY2026

Shareholders' equity$420.3m, Q2 FY2026

Ginkgo Bioworks Holdings, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	1,049	944	840	730	616	562	312	204	111	167	144	84.5
Current assets	$m	1,142	1,002	903	783	662	603	565	523	506	472	410	333
Total assets	$m	2,026	1,665	1,582	1,625	1,481	1,377	1,293	1,231	1,189	1,120	1,033	990
Current liabilities	$m	168	164	169	166	114	107	116	96.7	115	96.0	79.6	72.7
Total liabilities	$m	774	568	594	792	683	661	646	618	629	611	590	570
Shareholders' equity	$m	1,253	1,097	987	833	798	716	647	613	560	509	443	420

Cash flow

Operating cash flow−$44.3m, Q2 FY2026

Capital expenditure$2.6m, Q2 FY2026

Ginkgo Bioworks Holdings, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$m	(73.6)	(57.8)	(89.3)	(84.4)	(104)	(42.4)	(51.5)	(40.3)	(31.6)	(47.7)	(46.7)	(44.3)
Capital expenditure	$m	4.4	3.4	6.7	27.0	15.1	13.7	7.6	0.0	0.0	0.0	1.9	2.6

Diluted shares (weighted)55.63m, Q3 FY2025

Ginkgo Bioworks Holdings, Inc., shares, quarterly
Line item	Unit	Q1 FY20222022-03-31	Q2 FY20222022-06-30	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30
Diluted shares (weighted)	m shares	1.6	1,621	1,631	1,917	1,933	48.8	50.1	51.4	52.2	54.2	54.9	55.6

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. Listed shows no prices and gives no investment advice.

Ginkgo Bioworks Holdings, Inc.

Income statement

Balance sheet

Cash flow

Shares